JPH0120903B2 - - Google Patents
Info
- Publication number
- JPH0120903B2 JPH0120903B2 JP56196267A JP19626781A JPH0120903B2 JP H0120903 B2 JPH0120903 B2 JP H0120903B2 JP 56196267 A JP56196267 A JP 56196267A JP 19626781 A JP19626781 A JP 19626781A JP H0120903 B2 JPH0120903 B2 JP H0120903B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- antibody
- column
- antibodies
- malignant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004369 blood Anatomy 0.000 claims description 34
- 239000008280 blood Substances 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 25
- 210000001124 body fluid Anatomy 0.000 claims description 18
- 239000010839 body fluid Substances 0.000 claims description 18
- 229920000936 Agarose Polymers 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 description 23
- 238000000034 method Methods 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 8
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000004087 circulation Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101000827784 Rattus norvegicus Alpha-fetoprotein Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56196267A JPS5897366A (ja) | 1981-12-08 | 1981-12-08 | 血液及び体液物質の除去装置 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56196267A JPS5897366A (ja) | 1981-12-08 | 1981-12-08 | 血液及び体液物質の除去装置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5897366A JPS5897366A (ja) | 1983-06-09 |
| JPH0120903B2 true JPH0120903B2 (en, 2012) | 1989-04-19 |
Family
ID=16354957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56196267A Granted JPS5897366A (ja) | 1981-12-08 | 1981-12-08 | 血液及び体液物質の除去装置 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5897366A (en, 2012) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015522577A (ja) * | 2012-06-28 | 2015-08-06 | フレセニウス メディカル ケア ドイチェランド ゲーエムベーハーＦｒｅｓｅｎｉｕｓ Ｍｅｄｉｃａｌ Ｃａｒｅ Ｄｅｕｔｓｃｈｌａｎｄ ＧｍｂＨ | 体外灌流装置 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59144460A (ja) * | 1983-02-07 | 1984-08-18 | テルモ株式会社 | 体液成分除去装置 |
| DE102009034150A1 (de) * | 2009-07-20 | 2011-01-27 | Fresenius Medical Care Deutschland Gmbh | Adsorbens zur Adsorption von Hepcidin |
| JP5227271B2 (ja) * | 2009-07-27 | 2013-07-03 | 旭化成メディカル株式会社 | 血液からウイルス及びサイトカインを除去するシステム |
-
1981
- 1981-12-08 JP JP56196267A patent/JPS5897366A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015522577A (ja) * | 2012-06-28 | 2015-08-06 | フレセニウス メディカル ケア ドイチェランド ゲーエムベーハーＦｒｅｓｅｎｉｕｓ Ｍｅｄｉｃａｌ Ｃａｒｅ Ｄｅｕｔｓｃｈｌａｎｄ ＧｍｂＨ | 体外灌流装置 |
| US9861735B2 (en) | 2012-06-28 | 2018-01-09 | Fresenius Medical Care Deutschland Gmbh | Extracorporeal perfusion apparatus |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5897366A (ja) | 1983-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5122112A (en) | Antigen-specific removal of circulating immune complexes | |
| US4361484A (en) | Process for treating and/or removal of substances from liquid, especially whole blood | |
| US4787974A (en) | Blood purification | |
| US5215927A (en) | Method for immunoselection of cells using avidin and biotin | |
| US4770774A (en) | Column for removing β2 -microglobulin | |
| CA1086235A (en) | Continuous removing system of blood substances by extra corporeal circulation | |
| US4714556A (en) | Blood purification | |
| EP0056977B1 (en) | Immune adsorbent, adsorbing device and blood purifying apparatus | |
| US8865172B2 (en) | Method for reducing the number of unwanted molecules in bodily fluids | |
| JPS645010B2 (en, 2012) | ||
| US4865841A (en) | Methods and compositions for transient elimination of humoral immune antibodies | |
| AU2013224740A1 (en) | Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source | |
| US4512763A (en) | Method and apparatus for selective removal of constituents of blood | |
| EP0260280B2 (en) | Immunoselection method | |
| US5225353A (en) | Method for immunoselection of cells using avidin and biotin | |
| US20180093032A1 (en) | Targeted apheresis using binding agents or ligands immobilized on membranes | |
| EP0132534B1 (en) | Device for the extracorporeal treatment of body fluids | |
| EP0272792B1 (en) | Antigen-specific removal of circulating immune complexes | |
| JPH0120903B2 (en, 2012) | ||
| Terman et al. | Specific extraction of antigen in vivo by extracorporeal circulation over antibody immobilized in collodion-charcoal | |
| US4608253A (en) | Process for removing immune complex in blood by use of the immobilized pepsin | |
| US20100298753A1 (en) | Targeted apheresis for the treatment of rheumatoid arthritis | |
| JPH07106219B2 (ja) | インターロイキン２レセプターの除去装置およびそれを備えた血液体外循環装置 | |
| Pak et al. | Extraction of circulating gastrointestinal cancer antigen using solid-phase immunoadsorption system of monoclonal antibody-coupled membrane | |
| Panikkar et al. | Modified Polyacrylamide Microspheres as Immunosorbent: Trivandrum-695012. India. |